Nicox Receives Positive Feedback for NCX 470 in China

Nicox SA announced positive regulatory feedback for NCX 470 in China. Its partner, Ocumension Therapeutics, received encouraging pre-submission insights from the Chinese Center for Drug Evaluation. This feedback supports moving forward with a New Drug Application (NDA) for NCX 470, a treatment aimed at lowering intraocular pressure in patients with glaucoma or ocular hypertension. The NDA filing in China is expected soon after a submission to the U.S. FDA, anticipated in summer 2026.

Doug Hubatsch, Chief Scientific Officer of Nicox, expressed confidence in the forthcoming submissions, stating that recent positive outcomes heighten assurance. Globally, NCX 470 is licensed to different partners. Regulatory and commercialization responsibilities in China lie with Ocumension, while Kowa handles other markets.